Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SCI (Stem Cell Innovations) forms pact to explore bone-forming capacity of Pluricells:

This article was originally published in Clinica

Executive Summary

US firm Stem Cell Innovations (SCI) has linked up with the University of Twente, in Enschede, the Netherlands, to assess the bone-forming properties of its PluriCells, a type of pluripotent stem cells isolated from foetal tissue. Houston, Texas-based SCI will give the university access to its human pluripotent stem cell technology and know-how in return for a nonexclusive licence to intellectual property generated with the PluriCells. PluriCells are developed from foetal germ cells rather than viable embryos and are, therefore, excluded from the US 2002 ban on federally funded stem cell research.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT053223

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel